Today Digemid issued the conditional sanitary registration of Molnupiravir, thus allowing the commercialization of the oral treatment developed by the pharmaceutical company Merck Sharp & Dohmeaimed at treating mild and moderate cases of COVID.
The pharmaceutical company -through a statement- explained that the drug “has demonstrated efficacy and safety in reducing hospitalizations and deaths from COVID-19”.
Molnupiravir is an antiviral -the firm detailed- that inhibits the replication of SARS-CoV-2, the causal agent of COVID-19 and that can be administered -even- to patients who are receiving other treatments because it presents low risk in interaction with other medications.
Recently multiple studies in-vitro Independent studies developed in the United States, Germany, Poland, Belgium, the Czech Republic and the Netherlands show that Molnupiravir has consistent antiviral activity once morest omicron, the predominant variant currently circulating in Peru and the world.
-Who can use it-
The pill – emphasized Merck Sharp & Dohme (MSD) – is prescribed to adults who are within the first 5 days from the onset of symptoms and who have at least one risk factor for developing severe disease.
Molnupiravir is taken as four 200-milligram capsules twice a day for 5 days with or without food to reduce the risk of the patient’s condition worsening.
Alberto La Rosa, medical manager of MSD, specified that “Molnupiravir is a medicine that is characterized by its simplicity of use. For patients, the treatment is simple, with a low risk of interaction with other drugs and without dietary requirements. The advantages for doctors are its prescription as a single prescription, without any additional supplements and with a favorable tolerability profile..”
La Rosa also specified that most of the people who participated in the phase 3 clinical trial of Molnupiravir are from Latin America, a continent that has its own characteristics and predominant variants of the virus.
The MSD treatment has demonstrated – he said – the required efficacy once morest COVID-19, for which it has been approved by the drug regulatory agencies of the United Kingdom, the United States, Denmark, Japan, Mexico, Colombia, among others.
-RECOMMENDED VIDEO-
